$NTRA

Marcus Gail Boxer sold $2.4M of NTRA

Marcus Gail Boxer sold 11,000 shares of Natera, Inc. (NTRA) at an average of $217.21 ($216.06–$218.82, $2.39M total) across 4 trades on 2026-06-05.

Original reporting
SEC EDGAR · Marcus Gail Boxer
Published Jun 10, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 1:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The only new fact is the director’s sale size, price range, and post-transaction holdings; it does not include any new company performance, guidance, or regulatory/product developments.

02

Market read

Traders may treat this as a mild sentiment datapoint, but it is unlikely to drive a sustained repricing without additional company catalysts.

03

What to watch

The article lacks context on total insider holdings over time, whether other insiders sold/bought, and whether the sale coincided with scheduled liquidity needs.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-09; transaction dated 2026-06-05

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera director Marcus Gail Boxer sold $2.39M of NTRA shares via open-market transactions disclosed on SEC Form 4.

Expected impact

Likely limited/short-lived impact; watch for follow-on insider activity or any concurrent company-specific news.

Evidence & confidence

This is a routine Form 4 insider transaction with no 10b5-1 plan stated and no accompanying fundamental update in the article.

Market effects

No direct sector read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Director sales can be pre-planned for diversification or tax needs; without a stated 10b5-1 plan, the market may overinterpret intent.

Key entities

  • Natera, Inc.

    Company whose shares were sold by a director in the reported Form 4.

  • Marcus Gail Boxer

    Director who executed open-market sales totaling ~$2.39M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.